Considering SIGLEC9 as a potential molecular target, our results suggest that the clinical effects of potential therapies based on inhibiting SIGLEC9 expression may be consistent, regardless of the mutation status of the KRAS, NRAS, BRAF, PIK3CA, and AKT genes in CRC patients. This evidence concerns the gene BRAF and colorectal carcinoma.